• David Bonda, Katherine A Kelly, Scott Boop, Abdullah H Feroze, Stephanie C Randle, Mike Bindschadler, Ahmad Marashly, James Owens, Jason Lockrow, Xiuhua Bozarth, Edward Novotny, Seth Friedman, Hannah E Goldstein, Benjamin L Grannan, Sharon Durfy, Jeffrey G Ojemann, Andrew L Ko, and Jason S Hauptman.
• Department of Neurological Surgery, University of Washington, Seattle, Washington, USA; Department of Neurology, University of Washington, Seattle, Washington, USA; Division of Pediatric Neurology, Seattle Children's Hospital, Seattle, Washington, USA.
• World Neurosurg. 2024 May 1; 185: e631e639e631-e639.

BackgroundSurgical management of pediatric patients with nonlesional, drug-resistant epilepsy, including patients with Lennox-Gastaut syndrome (LGS), remains a challenge given the lack of resective targets in most patients and shows seizure freedom rates <50% at 5 years. The efficacy of deep brain stimulation (DBS) is less certain in children than in adults. This study examined clinical and seizure outcomes for pediatric patients with LGS undergoing DBS targeting of the centromedian thalamic nuclei (CMTN).MethodsAn institutional review board-approved retrospective analysis was performed of patients aged ≤19 years with clinical diagnosis of LGS undergoing bilateral DBS placement to the CMTN from 2020 to 2021 by a single surgeon.ResultsFour females and 2 males aged 6-19 years were identified. Before surgery, each child experienced at least 6 years of refractory seizures; 4 children had experienced seizures since infancy. All took antiseizure medications at the time of surgery. Five children had previous placement of a vagus nerve stimulator and 2 had a previous corpus callosotomy. The mean length of stay after DBS was 2 days. No children experienced adverse neurologic effects from implantation; the mean follow-up time was 16.3 months. Four patients had >60% reduction in seizure frequency after surgery, 1 patient experienced 10% reduction, and 1 patient showed no change. No children reported worsening seizure symptoms after surgery.ConclusionsOur study contributes to the sparse literature describing CMTN DBS for children with drug-resistant epilepsy from LGS. Our results suggest that CMTN DBS is a safe and effective therapeutic modality that should be considered as an alternative or adjuvant therapy for this challenging patient population. Further studies with larger patient populations are warranted.Copyright © 2024 Elsevier Inc. All rights reserved.

23 keywords...

hide…